← The Wire
CABANasdaq
Cabaletta Bio, Inc.
Biological Products, (No Diagnostic Substances) · DE · CIK 1759138
Develops engineered T cell therapies for autoimmune diseases by ablating B cells to reset the immune system
$491M
Market cap
$3.11
Last close
+2.3%
1D
+3.3%
5D
5.5M
Volume
Price · last 39 sessions-18.8%
May 4L $2.80 · H $4.15Jun 29
164
Total filings
Jun 11, 2026
Last filing
12/31
Fiscal year end
SC 13GSC 13GNov 14, 2024SC 13GSC 13GAug 22, 2024SC 13G13G MONTHLY FILING - CABAJun 6, 2024SC 13GSC 13GJan 24, 2024SC 13GSC 13GJan 8, 2024SC 13GSC 13GJun 1, 2023SC 13GSC 13GMay 26, 2023SC 13GSC 13GFeb 14, 2023SC 13GCABALETTA BIO, INC.Feb 10, 2023SC 13GSC 13GJan 13, 2023SC 13GSC 13GDec 23, 2022SC 13GSC 13GNov 7, 2022SC 13GCABALETTA BIO, INCOct 31, 2022SC 13GSC 13GOct 31, 2022SC 13GSC 13GAug 22, 2022SC 13GCABALETTA BIO, INC.Nov 1, 2021SC 13GSCHEDULE 13GFeb 16, 2021SC 13GCABALETTA BIO, INC.Jul 21, 2020SC 13GSC 13GNov 7, 2019SC 13GSC 13GNov 7, 2019SC 13GSC 13GOct 30, 2019
Insider Activity
◆ Cluster Buy · 8 insidersIn the 90 days to Jan 21, 2026: 8 insiders bought $296K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Jan 21, 2026 | Nichtberger StevenPresident & CEO | Buy | 45,000 | $2.24 | $101K |
| Jan 21, 2026 | Gavel SteveChief Commercial Officer | Buy | 22,170 | $2.27 | $50K |
| Jan 21, 2026 | Tomasello ShawnDirector | Buy | 22,725 | $2.21 | $50K |
| Jan 21, 2026 | Simon MarkDirector | Buy | 11,061 | $2.28 | $25K |
| Jan 21, 2026 | Binder GwendolynPresident, Science & Tech. | Buy | 11,312 | $2.19 | $25K |
| Jan 21, 2026 | Chang David J.Chief Medical Officer | Buy | 8,800 | $2.26 | $20K |
| Jan 21, 2026 | Gerard MichaelGeneral Counsel | Buy | 6,600 | $2.27 | $15K |
| Jan 21, 2026 | Bollard CatherineDirector | Buy | 4,405 | $2.27 | $10K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance